Cough Reduction in IPF With Nalbuphine ER

NCT05964335 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: NAL ER
DRUG: Placebo
DRUG: NAL ER
DRUG: NAL ER

Sponsor

Trevi Therapeutics